Search company, investor...
CivaTech Oncology company logo

CivaTech Oncology

civatechoncology.com

Founded Year

2006

Stage

Unattributed - V | Alive

Total Raised

$19.71M

Last Raised

$8M | 1 yr ago

About CivaTech Oncology

Civatech Oncology is a medical device company focused on the development of polymer based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for precise encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy.

Headquarters Location

2810 Meridian Parkway #144

Durham, North Carolina, 27713,

United States

919-314-5515

Missing: CivaTech Oncology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CivaTech Oncology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CivaTech Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CivaTech Oncology is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

11,653 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health IT

7,901 items

CivaTech Oncology Patents

CivaTech Oncology has filed 1 patent.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Medical physics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/24/2017

5/12/2020

Dosage forms, Drug delivery devices, Radiation therapy, Routes of administration, Medical physics

Grant

Application Date

7/24/2017

Grant Date

5/12/2020

Title

Related Topics

Dosage forms, Drug delivery devices, Radiation therapy, Routes of administration, Medical physics

Status

Grant

Latest CivaTech Oncology News

CivaTech Oncology selected to present at BIO International Conference

Jun 28, 2022

June 28, 2022 06:36 PM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--CivaTech Oncology Inc., a leading developer of radioactive cancer therapeutics made a presentation regarding the CivaSheet® at the annual Biotechnology Innovation Organization (BIO) Conference June 14, 2022 in San Diego California. BIO International connects top research and early stage innovations with industry and investors. CivaTech Oncology's CivaSheet® was supported in development and in clinical trials by National Institutes of Health/National Cancer Institute and the Small Business Innovation Research (SBIR). SBIR, a government program coordinated by the Small Business Administration, plays a valuable role in the start up of new companies developing meaningful products to change lives and improve cancer outcomes. SBIR grants have continued to support small businesses seeking commercialization even in the midst of a global pandemic. Funds from the NCI SBIR have helped CivaSheet® technology gain ground despite the challenging healthcare environment. Suzanne Babcock, CEO of CivaTech Oncology, indicated that “the role of the SBIR has been pivotal in developing the device and generating a platform that addresses many cancer types including non-small cell lung cancer, pancreatic, colorectal, head and neck, soft tissue sarcomas and more.” CivaSheet®, a novel bio-absorbable, internal radiation treatment, is implanted in less than 30 minutes in the operating room at the time of surgery. It prevents cancer recurrence by delivering a highly targeted dose of radiation directly to the surgical margin where residual cancer cells may remain. Results from clinical trials have shown remarkable improvements in therapeutic outcomes. CivaSheet® is a flexible, implantable intra-operative radiation therapy device (brachytherapy) which emits unidirectional radiation using integrated gold shielding. This provides a homogenous radiation dose on one side while protecting healthy tissues. This feature is entirely unique to CivaSheet® allowing physicians to safely deliver aggressive radiation doses immediately adjacent to healthy, sensitive tissue. No complications or radiation related side effects have been reported in patients to date. About CivaTech Oncology: For more information about CivaSheet or CivaTech Oncology, please visit www.civatechoncology.com or call 919-314-1515 (Randy Harrison). Taylor RJ, Todor D, Kaplan BJ, Stover W, Fields EC. “CivaSheet intraoperative radiation therapy for pancreatic cancer.” Brachytherapy. 2022 Mar-Apr;21(2):255-259. doi: 10.1016/j.brachy.2021.10.007 Contacts

CivaTech Oncology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CivaTech Oncology Rank

CivaTech Oncology Frequently Asked Questions (FAQ)

  • When was CivaTech Oncology founded?

    CivaTech Oncology was founded in 2006.

  • Where is CivaTech Oncology's headquarters?

    CivaTech Oncology's headquarters is located at 2810 Meridian Parkway, Durham.

  • What is CivaTech Oncology's latest funding round?

    CivaTech Oncology's latest funding round is Unattributed - V.

  • How much did CivaTech Oncology raise?

    CivaTech Oncology raised a total of $19.71M.

  • Who are the investors of CivaTech Oncology?

    Investors of CivaTech Oncology include One North Carolina Small Business Program and National Cancer Institute.

  • Who are CivaTech Oncology's competitors?

    Competitors of CivaTech Oncology include Decipher Biosciences, Exagen, Augmenix, Integrated Diagnostics, Micrima and 14 more.

Compare CivaTech Oncology to Competitors

P
Prognomix

Predict to Prevent  Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development  of  presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention

C
Cellpoint Diagnostics

CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.

X
Xoft Microtube

Xoft is engaged in the practice of radiation oncology through electronic brachytherapy with its miniaturized x-ray tube technology. It's first product, the Axxent Electronic Brachytherapy System applies radiation directly to a tumor bed within the body without the use of radioactive isotopes, heavy shielding, or major capital equipment.

N
NeoDiagnostix

NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

C
Calpyso Medical

Calypso Medical provides technologies in the radiation oncology market

R
Radiation Shield Technologies

Radiation Shield Technologies (RST) is the world leader in the research, design and production of personal protection systems for ionizing and nuclear radiation. The company's core technology, DemronTM , is specifically engineered to combine radiation protection with "ease of use" in order to maximize effective radiological defense. RST's primary goal is to ensure that all DemronTM products are of the highest protective quality. This is achieved by working closely with the company's end users, developing new standards of personal radiation protection, and meeting the specific needs of those groups most at risk of exposure. After almost a decade of development, RST is proud to introduce DemronTM to the industries, governments and everyday people who, until now, have had no options for true personal radiation protection.n

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.